{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:20:54Z","timestamp":1792804854709,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted sequencing for somatic mutations across the hotspots of 50 cancer-related genes was performed using biopsy specimens to investigate whether clinicopathological factors and genomic alterations correlated with prognosis in locally advanced cervical cancer. Seventy patients diagnosed with International Federation of Obstetrics and Gynecology (FIGO) stage III to IVA cervical cancer underwent radiotherapy or concurrent chemoradiotherapy at the National Cancer Center Hospital between January 2008 and December 2017. Mutations were detected in 47 of 70 [67% of cases; frequency of genetic alterations was as follows: <jats:italic>PIK3CA<\/jats:italic> (51%), <jats:italic>FBXW7<\/jats:italic> (10%), <jats:italic>PTEN<\/jats:italic> (7.1%), and <jats:italic>TP53<\/jats:italic> (5.7%)]. The Cancer Genome Atlas (TCGA) datasets showed a similar distribution of somatic mutations, but <jats:italic>PIK3CA<\/jats:italic> mutation frequency was significantly higher in our cohort than in TCGA datasets (<jats:italic>P<\/jats:italic>\u2009=\u20090.028). Patients with <jats:italic>TP53<\/jats:italic> mutation were significantly related to poor progression-free survival (PFS) (hazard ratio [HR]\u2009=\u20093.53, <jats:italic>P<\/jats:italic>\u2009=\u20090.042). Patients with tumor diameters\u2009&gt;\u200970\u00a0mm were associated with poor prognosis (HR\u2009=\u20092.96, <jats:italic>P<\/jats:italic>\u2009=\u20090.0048). Patients with non-HPV16\/18 genotypes had worse prognosis than those with HPV16\/18 genotypes (HR\u2009=\u20092.15, <jats:italic>P<\/jats:italic>\u2009=\u20090.030). Hence, patients with locally advanced cervical cancer, <jats:italic>TP53<\/jats:italic> mutation, large tumor diameter, and non-HPV16\/18 genotype were independently correlated with poor PFS, despite concurrent chemoradiotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-98527-2","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T10:03:21Z","timestamp":1632823401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["TP53 mutants and non-HPV16\/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Ikumi","family":"Kuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sou","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi Kobayashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"98527_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"98527_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","volume":"382","author":"EJ Crosbie","year":"2013","unstructured":"Crosbie, E. J., Einstein, M. H., Franceschi, S. & Kitchener, H. C. Human papillomavirus and cervical cancer. Lancet 382, 889\u2013899 (2013).","journal-title":"Lancet"},{"issue":"670","key":"98527_CR3","first-page":"e671","volume":"213","author":"JD Wright","year":"2015","unstructured":"Wright, J. D. et al. Population-level trends in relative survival for cervical cancer. Am. J. Obstet. Gynecol. 213(670), e671\u2013e677 (2015).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"98527_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet 393, 169\u2013182 (2019).","journal-title":"Lancet"},{"key":"98527_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2012.04.036","volume":"126","author":"T Toita","year":"2012","unstructured":"Toita, T. et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol. Oncol. 126, 211\u2013216 (2012).","journal-title":"Gynecol. Oncol."},{"key":"98527_CR6","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1200\/JCO.2004.00.0497","volume":"23","author":"R Lanciano","year":"2005","unstructured":"Lanciano, R. et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A gynecologic oncology group study. J. Clin. Oncol. 23, 8289\u20138295 (2005).","journal-title":"J. Clin. Oncol."},{"key":"98527_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(03)13778-6","volume":"361","author":"SE Waggoner","year":"2003","unstructured":"Waggoner, S. E. Cervical cancer. Lancet 361, 2217\u20132225 (2003).","journal-title":"Lancet"},{"key":"98527_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000462","volume":"3","author":"C Vora","year":"2018","unstructured":"Vora, C. & Gupta, S. Targeted therapy in cervical cancer. ESMO Open 3, e000462 (2018).","journal-title":"ESMO Open"},{"key":"98527_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung, H. C. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 37, 1470\u20131478 (2019).","journal-title":"J. Clin. Oncol."},{"key":"98527_CR10","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1002\/cncr.33136","volume":"126","author":"LR Duska","year":"2020","unstructured":"Duska, L. R. et al. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer 126, 4948\u20134956 (2020).","journal-title":"Cancer"},{"key":"98527_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734\u2013743 (2014).","journal-title":"N. Engl. J. Med."},{"key":"98527_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ygyno.2019.05.018","volume":"154","author":"K Suzuki","year":"2019","unstructured":"Suzuki, K. et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol. Oncol. 154, 554\u2013557 (2019).","journal-title":"Gynecol. Oncol."},{"key":"98527_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejogrb.2019.01.028","volume":"235","author":"ACM Queiroz","year":"2019","unstructured":"Queiroz, A. C. M. et al. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 235, 6\u201312 (2019).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"98527_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/ijgc-2018-000095","volume":"29","author":"Y Huang","year":"2019","unstructured":"Huang, Y. et al. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer. Int. J. Gynecol. Cancer 29, 459\u2013465 (2019).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"98527_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378\u2013384 (2017).","journal-title":"Nature"},{"key":"98527_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ygyno.2019.10.022","volume":"156","author":"S Hirose","year":"2020","unstructured":"Hirose, S. et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol. Oncol. 156, 203\u2013210 (2020).","journal-title":"Gynecol. Oncol."},{"key":"98527_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ygyno.2012.12.019","volume":"128","author":"JB McIntyre","year":"2013","unstructured":"McIntyre, J. B. et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol. Oncol. 128, 409\u2013414 (2013).","journal-title":"Gynecol. Oncol."},{"key":"98527_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011392","volume":"97","author":"B Lachkar","year":"2018","unstructured":"Lachkar, B. et al. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Medicine (Baltimore) 97, e11392 (2018).","journal-title":"Medicine (Baltimore)"},{"key":"98527_CR19","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/cncr.28288","volume":"119","author":"AA Wright","year":"2013","unstructured":"Wright, A. A. et al. Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776\u20133783 (2013).","journal-title":"Cancer"},{"key":"98527_CR20","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.18632\/oncotarget.23664","volume":"9","author":"P Grigsby","year":"2018","unstructured":"Grigsby, P. et al. Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. Oncotarget 9, 4061\u20134073 (2018).","journal-title":"Oncotarget"},{"key":"98527_CR21","doi-asserted-by":"publisher","first-page":"14035","DOI":"10.1038\/srep14035","volume":"5","author":"L Xiang","year":"2015","unstructured":"Xiang, L. et al. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci. Rep. 5, 14035 (2015).","journal-title":"Sci. Rep."},{"key":"98527_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ygyno.2020.08.020","volume":"159","author":"Y Yoshimoto","year":"2020","unstructured":"Yoshimoto, Y. et al. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol. Oncol. 159, 546\u2013553 (2020).","journal-title":"Gynecol. Oncol."},{"key":"98527_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3802\/jgo.2015.26.1.12","volume":"26","author":"D Endo","year":"2015","unstructured":"Endo, D. et al. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: A retrospective analysis in a Japanese cohort. J. Gynecol. Oncol. 26, 12\u201318 (2015).","journal-title":"J. Gynecol. Oncol."},{"key":"98527_CR24","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e4","volume":"29","author":"W Jiang","year":"2018","unstructured":"Jiang, W. et al. Mutational analysis of KRAS and its clinical implications in cervical cancer patients. J. Gynecol. Oncol. 29, e4 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"98527_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ygyno.2017.12.023","volume":"148","author":"L Xiang","year":"2018","unstructured":"Xiang, L. et al. ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecol. Oncol. 148, 311\u2013316 (2018).","journal-title":"Gynecol. Oncol."},{"issue":"432","key":"98527_CR26","first-page":"e431","volume":"217","author":"MK Halle","year":"2017","unstructured":"Halle, M. K. et al. Clinicopathologic and molecular markers in cervical carcinoma: A prospective cohort study. Am. J. Obstet. Gynecol. 217(432), e431-432 e417 (2017).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"98527_CR27","first-page":"141","volume":"21","author":"DR Lowy","year":"1996","unstructured":"Lowy, D. R. & Schiller, J. T. Human papillomavirus biology. J. Natl. Cancer Inst. Monogr. 21, 141\u2013143 (1996).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"98527_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejogrb.2015.10.006","volume":"195","author":"R Zhou","year":"2015","unstructured":"Zhou, R., Wei, C., Liu, J., Luo, Y. & Tang, W. The prognostic value of p53 expression for patients with cervical cancer: A meta analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 195, 210\u2013213 (2015).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"98527_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/his.14109","volume":"77","author":"KE Kortekaas","year":"2020","unstructured":"Kortekaas, K. E. et al. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. Histopathology 77, 92\u201399 (2020).","journal-title":"Histopathology"},{"key":"98527_CR30","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/annonc\/mdw426","volume":"27","author":"I Tinhofer","year":"2016","unstructured":"Tinhofer, I. et al. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. Ann. Oncol. 27, 2262\u20132268 (2016).","journal-title":"Ann. Oncol."},{"key":"98527_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0167-8140(01)00301-2","volume":"59","author":"J Alsner","year":"2001","unstructured":"Alsner, J., Sorensen, S. B. & Overgaard, J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 59, 179\u2013185 (2001).","journal-title":"Radiother. Oncol."},{"key":"98527_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hed.23837","volume":"37","author":"F Perri","year":"2015","unstructured":"Perri, F. et al. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck 37, 763\u2013770 (2015).","journal-title":"Head Neck"},{"key":"98527_CR33","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.cell.2018.07.034","volume":"174","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 174, 1034\u20131035 (2018).","journal-title":"Cell"},{"key":"98527_CR34","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2007.11.2995","volume":"25","author":"CH Lai","year":"2007","unstructured":"Lai, C. H. et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J. Clin. Oncol. 25, 3628\u20133634 (2007).","journal-title":"J. Clin. Oncol."},{"key":"98527_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pvr.2018.10.005","volume":"6","author":"M Onuki","year":"2018","unstructured":"Onuki, M. et al. Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors. Papillomavirus Res. 6, 41\u201345 (2018).","journal-title":"Papillomavirus Res."},{"key":"98527_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12879-017-2465-y","volume":"17","author":"D Hang","year":"2017","unstructured":"Hang, D. et al. Independent prognostic role of human papillomavirus genotype in cervical cancer. BMC Infect. Dis. 17, 391 (2017).","journal-title":"BMC Infect. Dis."},{"key":"98527_CR37","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/ijc.28902","volume":"135","author":"K Cuschieri","year":"2014","unstructured":"Cuschieri, K. et al. Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. Int. J. Cancer 135, 2721\u20132726 (2014).","journal-title":"Int. J. Cancer"},{"key":"98527_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1476-4598-10-71","volume":"10","author":"FE Henken","year":"2011","unstructured":"Henken, F. E. et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol. Cancer 10, 71 (2011).","journal-title":"Mol. Cancer"},{"key":"98527_CR39","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"98527_CR40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric, D. et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study. J. Clin. Oncol. 36, 1291\u20131299 (2018).","journal-title":"J. Clin. Oncol."},{"key":"98527_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3322\/caac.21578","volume":"69","author":"C Chargari","year":"2019","unstructured":"Chargari, C. et al. Brachytherapy: An overview for clinicians. CA Cancer J. Clin. 69, 386\u2013401 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"98527_CR42","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum, M. J. et al. ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862\u2013D868 (2016).","journal-title":"Nucleic Acids Res."},{"key":"98527_CR43","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami, K. et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110, 1480\u20131490 (2019).","journal-title":"Cancer Sci."},{"key":"98527_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98527-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:00:24Z","timestamp":1670083224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98527-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98527"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98527-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19261"}}